Introduction
Drug rash with eosinophilia and systemic symptoms (DRESS) is also a rare but potentially life threatening reaction that has been linked to several common drugs [1, 2, 3] .
Clinical and biological manifestations included fever, generalized rash, lymphadenopathy, hypereosinophilia and multi visceral involvement. It is characterized by a prolonged latency period, 2 to 6 weeks after drug intake and persists for weeks despite discontinuation of the causative drug [4, 5, 6, 7] . It is associated with mortality of up to 10% [8] . Therefore, early diagnosis and the interruption of the culprit drug are crucial.
Its pathophysiology is complex and not fully understood. It appears be related to human herpes virus reactivation induced by somes drugs in a genetically predisposed patient [4] .
Carbamazepine, an aromatic anticonvulsivant drug widely prescribed in our country, is among the most frequently implicated drugs in the genesis of this syndrome [9, 10] . Recently, studies in European and Japanese patients showed a significant association between the syndrome induced by carbamazepine and HLA-A*31:01 [11, 12, 13, 14, 15, 16] . However, no studies have been performed in North African population to determine HLA genotypes of patients with DRESS syndrome induced by carbamazepine, knowing that HLA associations with drug hypersensitivity are generally ethnic-group specific.
Our aim is to investigate the association between the HLA class I genotype and carbamazepine-induced DRESS syndrome in a Tunisian population sample and find the genetic marker that can predict this severe systemic syndrome in a North African population sample.
Methods

Study population
We recruited case subjects that have DRESS syndrome induced by carbamazepine notified at regional pharmacovigilance center of sfax in a period from January 2006 to December 2015.
We also recruited control subjects who had received carbamazepine for at least 3 months without evidence of an adverse reaction. All case subjects and control subjects were of Tunisian ancestry.
A enquiry of pharmacovigilance was conducted for all case subjects according the French method of imputability (MFI) which is developed by Dongoumeau et al. in 1978 [17] and updated by Bégaud et al. [18] in 1985. Also, the diagnosis of DRESS syndrome was based on RegiSCAR criteria include at least 3 of the following 7 characteristics: 1) skin eruption, 2) fever (>38 C), 3) lymphadenopathy at least 2 sites, 4) involvement of at least 1 internal organ, 5) lymphocytosis (>4 Â 103/mL) or lymphocytopenia (10% or 700/ mL), and 7) thrombocytopenia (<120 Â 103/mL). Patients were classified into definite, probable, possible or no cases according to the RegiSCAR scoring system [19] .
Informed consent was obtained from all case and control subjects.
HLA-typing
HLA class I (A and B) typing was performed on freshly collected venous blood by the standard complement dependent microlymphocytotoxicity assay. A minimum of three antisera for each HLA class I specificity were used.
DNA typing HLA class I (A) alleles was checked by the polymerase chain reaction amplification Sequence Specific Oligonucleotide Probes (SSO) (reverse-SSO assay).
High resolution HLA DNA Kit based on the Luminex technology (One Lambda 1 ) was used according to the manufacturer's protocol [20] .
Statistical analyses
Fisher's exact test was performed and the odd ratios (OR) were calculated using SPSS version 20.0 to compare the carrier frequencies of HLA alleles between the case and control subjects. Correction for multiple comparisons was performed for the alleles in which statistical significance were detected. Statistical significance was set at P < 0.05.
Results
Characteristics of the study population
The case group was fourteen patients who had DRESS syndrome induced by carbamazepine and notified at regional pharmacovigilance center of sfax. The mean age of the patients with DRESS syndrome was 48.80 years, and the most affected patients were aged between 50 and 60 years. 9 patients were male and 5 patients were female. In this group, 4 subjects are hypertensive, one diabetic, and 3 patients have personal or familial history of atopy. In all cases, carbamazepine was taken orally as 200 mg tablets. The most common carbamazepine treatment dose was 400 mg (2 tablets/day). The mean duration of carbamazepine treatment were 34 days and extremes ranging from 7 days to 116 days.
Skin manifestations such as erythema or maculopapular eruption, fever and hypereosinophilia were observed in all case subjects. Other systemic symptoms such as adenopathy were presented in 4 cases, hepatitis in 10 patients, renal failure in 7 patients, leukocytosis in 5 cases et pancreatitis in one case.
Four patients used corticosteroids and five other cases used topical corticosteroids. Outcome was favorable with improvement of symptoms in all patients.
An enquiry of pharmacovigilance according the French method of imputability, was conducted for all cases group subjects. Imputability score was coted possible in 9 cases (C2S2I2B3) and likely in 5 cases (C3S2I3B3). Also, REGISCAR have used to classify all case group subjects. Imputability score was coted possible in one case, probable in 9 cases and definite in 4 cases.
We evaluated HLA class I genotypes of only seven patients among fourteen in the case group. The seven other patients refused to realize this genotyping test. HLA-A31 antigen was present in four patients that we have completed HLA typing by molecular biology method. Following this genotype test, we detected HLA-A*31: 01 allele in these 4 cases (4/7 was 57.10%). Three cases with the HLA-A*31:01 allele were classified as definite case according REGISCAR. Other case was classified as probable.
Clinical characteristics and HLA-A genotyping of the cases group were summered in Table 1 .
The control group was twenty-five carbamazepine tolerants subjects. The mean age of controls was 45.20 years. The most represented age groups are between 50 and 60 years. In this group, we have 20 males subjects and 5 females. 5 subjects are diabetic, 3 others are hypertensive, 13 subjects have personal or familial history of atopy, 2 cases have renal failure and one subject has an autoimmune disease.
Similarly, to cases group, all control subjects take carbamazepine orally as 200 mg tablets. The daily carbamazepine treatment dose was variable from 200 mg to 1600 mg/day (1 to 8 tablets/day). The most common dose was 800 mg/day. The mean duration of carbamazepine treatment were 11 years and extremes ranging from 6 months to 30 years.
We evaluated also, HLA class I genotypes for twenty-five control group subjects. We detected HLA-A*31: 01 in only one subject in this group (1/25 was 4%). The detailed results of clinical characteristics and HLA-A genotyping of the controls group are presented in Table 2 .
Finally, we compared the HLA-A*31:01 allele frequencies of the carbamazepine-DRESS syndrome group with those of the carbamazepine-tolerant controls. The carrier frequency of HLA-A*31: 01 allele in the cases group was also significantly higher than in the controls group (57, 10% vs 4% P = 0,004). Odds ratio is estimated 32 (OR = 32 [2.6; 389.2]).
Discussion
Severe drug cutaneous reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and DRESS syndrome represent 2% of all drug reactions [20] . According to many authors, the incidence of DRESS syndrome in general population is estimated to be 1/1000 to 1/10000 new exposures to the drug [21, 22, 23, 24] .
Aromatic anticonvulsivants are the most common causes of DRESS [10] . Its incidence is estimated to 1/1500 drug exposure [3, 25, 26] . In fact, in the literature review carried out between 1997 and 2009, Cacoub et al found that carbamazepine represented 1/3 of all drugs incriminated in the genesis of DRESS syndrome during this period [27] In the present study, the incidence of carbamazepine-induced DRESS syndrome between 2006 and 2015 was 0.7% of all drug reactions reported in regional pharmacovigilance center during this period. These cases represent 31% (14 cases/45 cases) of all reported cases of DRESS syndrome.
Racial predominance to develop DRESS syndrome is discussed. In fact, Lebrun-Vignes and al found a high incidence of DRESS syndrome induced by aromatic anticonvulsivants in the African black population and it seems more severe and prolonged in whom these drugs are widely prescribed [28] Pathophysiology of this drug reaction is too complex and not fully understood. It seems to be an allergic delayed reaction type IV b result to accumulation of carbamazepine toxic metabolites. Indeed, aromatic anticonvulsivants have been shown to activate drug-specific T cells, which secrete interferon-gamma, interleukin-5, and other cytokines upon drug stimulation. Macrophages may also be activated to release tumor necrosis factor, likely playing a role in the severity of tissue damage It appears that the reactivation of herpes viruses has also been shown to play a role in the pathogenesis of DRESS syndrome. There are complex interactions between herpesviruses, antiviral immune and drug-specific immune responses observed in a genetically predisposed patient [4, 29, 30, 31, 32] . Indeed, many studies have demonstrated recently that individuals with specific human leukocyte antigen (HLA) haplotypes are predisposed to developing DRESS syndrome when exposed to an inciting drug. They were focused on the association between certain HLA alleles and DRESS syndrome, such as HLA-B*58: 01 is strongly associated with allopurinol-DRESS syndrome [33] and HLA-B*57: 01 is significantly associated with DRESS syndrome induced by abacavir [34] . Similarly, many immunogenetic studies have shown a significant association between HLA-A*31:01 and carbamazepine-induced hypersensitivity reaction in the populations of Europeans, Japanese, Korean and Han chinese [12, 13, 14, 15, 16] .
In healthy individuals, the frequency of HLA-A*31: 01 allele varies among different ethnic groups. It is 2 to 5% in the European population [16] . This frequency is comparable with Korean individuals (5%) and is lower among Han Chinese on average 2% [35, 16] . However, it is a common allele among Japanese individuals in whom the allele frequency is about 9% [35, 16] . As for the African population, HLA-A*31:01 is a very rare allele and its frequency is on average 1% [35] . Indeed, the prevalence of this allele is estimated at 1.22% in the Tunisian population [36] . There have been no reports on whether HLA-A*31:01 is linked to carbamazepine-induced hypersensitivity in african patients [35] . Thus, we conducted the present study on cases and controls group.
In the European population, Cormack and al in 2011 conducted a study about 22 patients with DRESS syndrome induced by carbamazepine and 257 controls subjects. They showed the presence of the HLA-A * 31: 01 in 40% of cases vs 4.9% controls. They report that the presence of HLA-A*31:01 allele increases the risk of hypersensitivity to 26%, wheras its absence reduces the risk to 3, 8% [16, 37] . Similarly, Kaniwa and al reported in their review that HLA-A* 31: 01 was detected in 10 patients among 17 cases, 58% vs only 3% in controls [35] . In addition, Anjum and al reported the cases of two patients with DRESS syndrome induced by carbamazepine and that presented both HLA-A*31: 01 [13] . In another study, the allele HLA-A*31: 01 was detected in 37% of patients with carbamazepine-DRESS syndrome vs 4% of controls [12] .
In the Japanese population, the allele HLA-A*31: 01 is also a predictor factor to induce carbamazepine-DRESS syndrome [14] . Indeed, Kashiwagi and al conducted in 2008 a study of 22 patients with carbamazepine-DRESS syndrome. They showed the existence of an association between HLA-A*31: 01 and the DRESS syndrome and its presence increases the risk of its occurrence [38] . In 2013, Kaniwa and al reported that this allele was detected in 58% of cases (36 cases) vs 12% of controls (240 controls subjects) [35] . Another study comparing 24 cases of DRESS syndrome induced by carbamazepine and 450 controls subjects confirmed the presence of the HLA-A*31: 01 to 59% vs. 14% of controls [12] .
In Chinese Han population, the association between HLA-A*31:01 and the occurrence of this syndrome was also discussed. A study was done in 2014, has objectified the presence of the HLA-A*31: 01 in 7 patients among 23 cases (30.4%) and at 5 among 152 controls subjects (3.3%) [39] . However, this allele was detected much less in another study conducted by Kaniwa and al who have notified the HLA-A* 31: 01 in 15% of cases vs 2% of controls subjects [35] .
Similarly, in the Korean population, the association between the HLA-A*31: 01 and the DRESS syndrome induced by carbamazepine was also notified. Indeed, Kim and al conducted a study in 2011 focused on three Korean populations' samples formed by 17 patients with DRESS syndrome induced by carbamazepine, 50 controls subjects treated with carbamazepine without any adverse effects and 485 subjects among a general population. HLA typing was conducted for these three groups and objectified HLA-A*31: 01 at 58.8%, 14% and 10.3% respectively [40] .
In the North American population, A study conducted in 2013 on 6 North American children with DRESS syndrome and 91 controls children showed a significant association between HLA-A*31: 01 and the occurrence of this syndrome. Indeed, this allele was present in 50% of cases vs 3.3% of controls [41] .
As for North Africa, to our knowledge no study has been performed to investigate the genetic predisposition of this population of carbamazepine-DRESS syndrome. Our present study focused on 7 cases of carbamazepine-DRESS syndrome from southern Tunisia and 25 controls subjects. We objectified the HLA-A*31: 01 allele in 57.1% of cases (4/7) vs 4% of controls (p = 0.004). Although statistical analysis had limited value because our small sample size, there was significant association between HLA-A*31: 01 and occurrence of this severe side effect.
Some authors have suggested another association between HLA-B*15: 02 and DRESS syndrome. Face this hypothesis, studies have been performed on Chinese populations found no association between the presence of HLA-B*15:02 and carbamazepine-DRESS syndrome [42] . In fact, this allele was not detected in any case of DRESS syndrome but it was present in 0.07% of controls [39] . Another study was conducted on a Vietnamese population has found no association between this allele and the occurrence of DRESS syndrome induced by carbamazepine [43] . These constatations was confirmed also by Amstutz and al [12] . However, HLA-B*15:02 was associated with the occurrence of stevens johnson syndrome (SJS) and toxic epidermal necrolysis (NET) [44, 45, 46, 47] . Similarly to literature, HLA-B*15:02 was not detected in any of our patients.
Finally, Shi YW and collaborators confirmed recently in 2017 a strong association between HLA-A*24:02 and Stevens-Johnson syndrome induced by the aromatic antiepileptic drugs in the southern Han Chinese [48] . In the present study HLA-A*24:02 was not present in any of our patients. This may be related to our small sample size. A study of the genetic profile of a large sample may confirm or disprove this finding.
Conclusion
In conclusion, DRESS syndrome induced carbamazepine is a serious side effect that is associated with mortality of up 10%. HLA-A*31:01 allele was significantly associated with carbamazepine-DRESS syndrome in various non-African populations. As for the population of North Africa, we successfully demonstrated this association.Although this result need to be confirmed in a large sample due to the current small sample size, the finding imply that HLA-A*31:01 may be a risk allele for carbamazepine-DRESS syndrome in North African population. This discovery is beneficial to forecasting carbamazepine-DRESS syndrome in North African population.
